WGU D116 ADVANCED PHARMACOLOGY FINAL EXAM PRACTICE | STUDY GUIDE
| TESTBANK | PRACTICE QUESTIONS & ANSWERS | COMPREHENSIVE PRACTICE
EXAM | ADVANCED REVIEW | LATEST UPDATE 2026/2027
Examiner:
Western Governors University (WGU)
## TABLE OF CONTENTS
1. Principles of Clinical Pharmacokinetics and Pharmacodynamics
2. Autonomic Nervous System Pharmacology
3. Cardiovascular Pharmacotherapeutics
4. Endocrine Pharmacology
5. Anti-Infective Agents and Antimicrobial Stewardship
6. Neurologic and Psychiatric Pharmacology
7. Pain Management and Controlled Substances
8. Respiratory and Gastrointestinal Pharmacology
9. Special Populations and Medication Safety
10. Drug Interactions, Monitoring, and Clinical Decision-Making
## DESCRIPTION
This comprehensive practice question set is designed to help learners prepare for
advanced pharmacology assessments by emphasizing clinical reasoning, evidence-
informed prescribing principles, medication safety, pharmacokinetics,
pharmacodynamics, adverse drug reactions, and therapeutic decision-making across
major body systems. The questions reflect the depth and complexity commonly
encountered in graduate-level nursing pharmacology coursework and are intended
solely as an educational study resource rather than an actual examination. Learners
will strengthen their ability to interpret patient scenarios, recognize contraindications,
evaluate drug interactions, adjust therapy for special populations, apply monitoring
strategies, and prioritize safe, patient-centered pharmacologic management using
challenging multiple-choice questions accompanied by detailed explanations.
QUESTION 1.
,A 72-year-old patient with chronic kidney disease (eGFR 28 mL/min/1.73 m²)
develops confusion after beginning a renally eliminated medication with a narrow
therapeutic index. Which pharmacokinetic principle best explains the patient's
increased toxicity?
A. Reduced renal clearance leading to prolonged elimination half-life
B. Increased first-pass metabolism
C. Increased hepatic enzyme induction
D. Reduced oral bioavailability
🔴 Correct Answer: A. Reduced renal clearance leading to prolonged elimination
half-life
🔵 Explanation: Reduced renal function decreases elimination of medications
primarily cleared by the kidneys, resulting in drug accumulation and increased
toxicity. Increased first-pass metabolism would decrease rather than increase systemic
exposure. Hepatic enzyme induction accelerates metabolism for susceptible drugs,
and reduced oral bioavailability generally lowers systemic drug concentrations.
QUESTION 2.
A patient taking warfarin is prescribed trimethoprim-sulfamethoxazole for a urinary
tract infection. Which outcome is most likely?
A. Reduced anticoagulant effect requiring dose escalation
B. Increased INR and elevated bleeding risk
C. No clinically significant interaction
D. Accelerated vitamin K synthesis
🔴 Correct Answer: B. Increased INR and elevated bleeding risk
🔵 Explanation: Trimethoprim-sulfamethoxazole inhibits warfarin metabolism and
can also reduce vitamin K-producing intestinal flora, increasing anticoagulant effects
and bleeding risk. The remaining options describe effects opposite to those expected
or are not clinically accurate.
,QUESTION 3.
A patient with heart failure and reduced ejection fraction is receiving an ACE
inhibitor but develops persistent angioedema. Which medication is generally the
most appropriate alternative?
A. Another ACE inhibitor at a lower dose
B. A direct renin inhibitor
C. An angiotensin receptor blocker, after careful assessment of risks and benefits
D. A nonselective beta-blocker alone
🔴 Correct Answer: C. An angiotensin receptor blocker, after careful assessment
of risks and benefits
🔵 Explanation: ACE inhibitor-associated angioedema generally requires permanent
discontinuation of ACE inhibitors. Depending on the clinical situation, an ARB may be
considered with caution because the risk of recurrent angioedema is substantially
lower but not zero. Rechallenging with another ACE inhibitor is generally avoided.
QUESTION 4.
A hospitalized patient receiving intravenous vancomycin develops worsening renal
function. Which monitoring parameter is currently emphasized to optimize efficacy
while minimizing nephrotoxicity?
A. Peak serum concentration only
B. Trough concentration only in every circumstance
C. Area under the concentration-time curve to minimum inhibitory concentration
ratio (AUC/MIC)
D. Serum osmolality
🔴 Correct Answer: C. Area under the concentration-time curve to minimum
inhibitory concentration ratio (AUC/MIC)
🔵 Explanation: Contemporary therapeutic drug monitoring emphasizes achieving an
appropriate AUC/MIC target because it better balances antimicrobial effectiveness
and nephrotoxicity risk. Peak-only or trough-only strategies are less optimal in many
clinical settings.
, QUESTION 5.
A patient with asthma experiences worsening wheezing shortly after initiation of
propranolol. What best explains this adverse event?
A. Beta-2 receptor blockade causing bronchoconstriction
B. Alpha-1 receptor stimulation
C. Muscarinic receptor antagonism
D. Histamine receptor activation
🔴 Correct Answer: A. Beta-2 receptor blockade causing bronchoconstriction
🔵 Explanation: Nonselective beta-blockers inhibit beta-2 receptors within bronchial
smooth muscle, promoting bronchoconstriction and worsening asthma symptoms.
The remaining receptor mechanisms do not adequately explain this clinical
presentation.
QUESTION 6.
A patient with type 2 diabetes, chronic kidney disease, and albuminuria requires
additional glucose-lowering therapy with demonstrated renal and cardiovascular
benefit. Which drug class is generally preferred if no contraindication exists?
A. Sulfonylureas
B. Thiazolidinediones
C. SGLT2 inhibitors
D. Meglitinides
🔴 Correct Answer: C. SGLT2 inhibitors
🔵 Explanation: SGLT2 inhibitors provide meaningful cardiovascular and renal
protection in many patients with chronic kidney disease and type 2 diabetes while
also improving glycemic control. Sulfonylureas and meglitinides primarily reduce
glucose without comparable renal outcome benefits, while thiazolidinediones may
worsen fluid retention.
| TESTBANK | PRACTICE QUESTIONS & ANSWERS | COMPREHENSIVE PRACTICE
EXAM | ADVANCED REVIEW | LATEST UPDATE 2026/2027
Examiner:
Western Governors University (WGU)
## TABLE OF CONTENTS
1. Principles of Clinical Pharmacokinetics and Pharmacodynamics
2. Autonomic Nervous System Pharmacology
3. Cardiovascular Pharmacotherapeutics
4. Endocrine Pharmacology
5. Anti-Infective Agents and Antimicrobial Stewardship
6. Neurologic and Psychiatric Pharmacology
7. Pain Management and Controlled Substances
8. Respiratory and Gastrointestinal Pharmacology
9. Special Populations and Medication Safety
10. Drug Interactions, Monitoring, and Clinical Decision-Making
## DESCRIPTION
This comprehensive practice question set is designed to help learners prepare for
advanced pharmacology assessments by emphasizing clinical reasoning, evidence-
informed prescribing principles, medication safety, pharmacokinetics,
pharmacodynamics, adverse drug reactions, and therapeutic decision-making across
major body systems. The questions reflect the depth and complexity commonly
encountered in graduate-level nursing pharmacology coursework and are intended
solely as an educational study resource rather than an actual examination. Learners
will strengthen their ability to interpret patient scenarios, recognize contraindications,
evaluate drug interactions, adjust therapy for special populations, apply monitoring
strategies, and prioritize safe, patient-centered pharmacologic management using
challenging multiple-choice questions accompanied by detailed explanations.
QUESTION 1.
,A 72-year-old patient with chronic kidney disease (eGFR 28 mL/min/1.73 m²)
develops confusion after beginning a renally eliminated medication with a narrow
therapeutic index. Which pharmacokinetic principle best explains the patient's
increased toxicity?
A. Reduced renal clearance leading to prolonged elimination half-life
B. Increased first-pass metabolism
C. Increased hepatic enzyme induction
D. Reduced oral bioavailability
🔴 Correct Answer: A. Reduced renal clearance leading to prolonged elimination
half-life
🔵 Explanation: Reduced renal function decreases elimination of medications
primarily cleared by the kidneys, resulting in drug accumulation and increased
toxicity. Increased first-pass metabolism would decrease rather than increase systemic
exposure. Hepatic enzyme induction accelerates metabolism for susceptible drugs,
and reduced oral bioavailability generally lowers systemic drug concentrations.
QUESTION 2.
A patient taking warfarin is prescribed trimethoprim-sulfamethoxazole for a urinary
tract infection. Which outcome is most likely?
A. Reduced anticoagulant effect requiring dose escalation
B. Increased INR and elevated bleeding risk
C. No clinically significant interaction
D. Accelerated vitamin K synthesis
🔴 Correct Answer: B. Increased INR and elevated bleeding risk
🔵 Explanation: Trimethoprim-sulfamethoxazole inhibits warfarin metabolism and
can also reduce vitamin K-producing intestinal flora, increasing anticoagulant effects
and bleeding risk. The remaining options describe effects opposite to those expected
or are not clinically accurate.
,QUESTION 3.
A patient with heart failure and reduced ejection fraction is receiving an ACE
inhibitor but develops persistent angioedema. Which medication is generally the
most appropriate alternative?
A. Another ACE inhibitor at a lower dose
B. A direct renin inhibitor
C. An angiotensin receptor blocker, after careful assessment of risks and benefits
D. A nonselective beta-blocker alone
🔴 Correct Answer: C. An angiotensin receptor blocker, after careful assessment
of risks and benefits
🔵 Explanation: ACE inhibitor-associated angioedema generally requires permanent
discontinuation of ACE inhibitors. Depending on the clinical situation, an ARB may be
considered with caution because the risk of recurrent angioedema is substantially
lower but not zero. Rechallenging with another ACE inhibitor is generally avoided.
QUESTION 4.
A hospitalized patient receiving intravenous vancomycin develops worsening renal
function. Which monitoring parameter is currently emphasized to optimize efficacy
while minimizing nephrotoxicity?
A. Peak serum concentration only
B. Trough concentration only in every circumstance
C. Area under the concentration-time curve to minimum inhibitory concentration
ratio (AUC/MIC)
D. Serum osmolality
🔴 Correct Answer: C. Area under the concentration-time curve to minimum
inhibitory concentration ratio (AUC/MIC)
🔵 Explanation: Contemporary therapeutic drug monitoring emphasizes achieving an
appropriate AUC/MIC target because it better balances antimicrobial effectiveness
and nephrotoxicity risk. Peak-only or trough-only strategies are less optimal in many
clinical settings.
, QUESTION 5.
A patient with asthma experiences worsening wheezing shortly after initiation of
propranolol. What best explains this adverse event?
A. Beta-2 receptor blockade causing bronchoconstriction
B. Alpha-1 receptor stimulation
C. Muscarinic receptor antagonism
D. Histamine receptor activation
🔴 Correct Answer: A. Beta-2 receptor blockade causing bronchoconstriction
🔵 Explanation: Nonselective beta-blockers inhibit beta-2 receptors within bronchial
smooth muscle, promoting bronchoconstriction and worsening asthma symptoms.
The remaining receptor mechanisms do not adequately explain this clinical
presentation.
QUESTION 6.
A patient with type 2 diabetes, chronic kidney disease, and albuminuria requires
additional glucose-lowering therapy with demonstrated renal and cardiovascular
benefit. Which drug class is generally preferred if no contraindication exists?
A. Sulfonylureas
B. Thiazolidinediones
C. SGLT2 inhibitors
D. Meglitinides
🔴 Correct Answer: C. SGLT2 inhibitors
🔵 Explanation: SGLT2 inhibitors provide meaningful cardiovascular and renal
protection in many patients with chronic kidney disease and type 2 diabetes while
also improving glycemic control. Sulfonylureas and meglitinides primarily reduce
glucose without comparable renal outcome benefits, while thiazolidinediones may
worsen fluid retention.
